Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity.

[1]  J. Cairns,et al.  Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. , 1992, British Journal of Cancer.

[2]  I. Ellis,et al.  Hormone sensitivity in breast cancer: influence of heterogeneity of oestrogen receptor expression and cell proliferation. , 1991, European journal of cancer.

[3]  I. Ellis,et al.  c-erbB-2 oncoprotein expression in primary and advanced breast cancer. , 1991, British Journal of Cancer.

[4]  Tony Hunter,et al.  Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity , 1991, Cell.

[5]  A. Harris,et al.  Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: Neu and tamoxifen failure , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[6]  B. van der Burg,et al.  Stimulation of TPA-responsive element activity by a cooperative action of insulin and estrogen in human breast cancer cells. , 1990, Molecular endocrinology.

[7]  R W Blamey,et al.  Expression of epidermal growth factor receptor in breast carcinoma. , 1990, Journal of clinical pathology.

[8]  H. Lehväslaiho,et al.  Similar early gene responses to ligand-activated EGFR and neu tyrosine kinases in NIH3T3 cells. , 1990, Oncogene.

[9]  H. Roels,et al.  The neu‐oncogene protein as a predictive factor for haematogenous metastases in breast cancer patients , 1990, International journal of cancer.

[10]  G. Vinson,et al.  Epidermal growth factor in breast cancer. , 1990, The International journal of biochemistry.

[11]  J. Meldolesi,et al.  Activation of an EGFR/neu chimeric receptor: early intracellular signals and cell proliferation responses. , 1989, Oncogene.

[12]  J. Varley,et al.  An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer. , 1989, British Journal of Cancer.

[13]  V. Brown,et al.  Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts , 1989, Cell.

[14]  I. Ellis,et al.  Ki67 immunostaining in primary breast cancer: pathological and clinical associations. , 1989, British Journal of Cancer.

[15]  J. Farndon,et al.  EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTORS ASSOCIATED WITH LACK OF RESPONSE TO ENDOCRINE THERAPY IN RECURRENT BREAST CANCER , 1989, The Lancet.

[16]  H. Lehväslaiho,et al.  A chimeric EGF‐R‐neu proto‐oncogene allows EGF to regulate neu tyrosine kinase and cell transformation. , 1989, The EMBO journal.

[17]  J. Farndon,et al.  Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu. , 1989, Journal of steroid biochemistry.

[18]  D. Altman,et al.  An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. , 1988, British Journal of Cancer.

[19]  P. Nowell,et al.  Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Schlessinger,et al.  Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB‐2 protein in the mammary tumor cell line SK‐BR‐3. , 1988, The EMBO journal.

[21]  D. Stern,et al.  EGF‐stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions. , 1988, The EMBO journal.

[22]  M. J. van de Vijver,et al.  Immunohistochemical detection of the neu protein in tissue sections of human breast tumors with amplified neu DNA. , 1988, Oncogene.

[23]  M. Berger,et al.  Expression of the c‐erbB‐2 protein in normal and transformed cells , 1987, International journal of cancer.

[24]  W. Gullick,et al.  OVEREXPRESSION OF THE c-erbB-2 ONCOPROTEIN IN HUMAN BREAST CARCINOMAS: IMMUNOHISTOLOGICAL ASSESSMENT CORRELATES WITH GENE AMPLIFICATION , 1987, The Lancet.

[25]  T. Akiyama,et al.  A Mr = 190,000 glycoprotein phosphorylated on tyrosine residues in epidermal growth factor stimulated KB cells is the product of the c-erbB-2 gene. , 1987, Biochemical and biophysical research communications.

[26]  T. Yamamoto,et al.  The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. , 1986, Science.

[27]  R. Weinberg,et al.  p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity , 1986, Molecular and cellular biology.

[28]  H Stein,et al.  Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. , 1984, Journal of immunology.

[29]  R. Rubens,et al.  Assessment of response to therapy in advanced breast cancer. A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland , 1977, European journal of cancer.

[30]  R. Rubens,et al.  Assessment of response to therapy in advanced breast cancer. , 1977, British Journal of Cancer.

[31]  E. Benson.  Assessment of response to treatment in advanced breast cancer. British Breast Group. , 1974, Lancet.